Alexandra Gylfe
Founding Partner @ Nordic Science Investments
Helsinki, Finland
Alexandra Gylfe is a seed investor at Nordic Science Investments in Helsinki focused on Medical and Health Care. Alexandra Gylfe is the Founder of Nordic Science Investments. She previously worked at Helsinki Innovation Services as a Business Development Director. Alexandra Gylfe attended Aalto University Executive Education and Professional Development.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Alexandra Gylfe invests in
Stages Alexandra Gylfe invests in
Countries Alexandra Gylfe invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (40%)
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Health Diagnostics 2 (40%)
- SaaS 1 (20%)
Stage
- Seed 3 (60%)
- Pre-Seed 1 (20%)
- Series A 1 (20%)
Country
- Finland 4 (80%)
- Sweden 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AIATELLA transforms cardiovascular diagnostics by harnessing AI to automate quantification, detection, and interpretation of medical images across multiple imaging modalities. Their technology boosts efficiency, ensures standardized analysis, and enables precision medicine, addressing the global challenges of radiologist shortages and the risingburden of cardiovascular diseases. | $2.3M / Seed / Jun 04, 2025 | ||
| RNatives specializes in the field of biotechnology, focusing on the development of innovative RNA-based therapies. The company's expertise lies in RNA activation, particularly targeting VEGFA for the treatment of cardiovascular diseases. RNatives is dedicated to advancing its lead programs through rigorous research and development, aiming tooffer novel therapeutic options for conditions with unmet medical needs. With a team of skilled professionals, RNatives is committed to pushing the boundaries of biotechnology to improve patient outcomes. | $1.6M / Seed / May 27, 2025 | ||
| Next generation Dried Blood Spot sampling – separating cells and plasma at the point of collection. | $1.8M / Seed / May 09, 2025 | ||
| Solid IO believes cancer care should be as precise and personal as possible. Solid IO’s tumor-on-chip platform is transforming oncology, delivering real-time, patient-specific insights that empower clinicians to make life-changing treatment decisions. With Solid IO, the next era of precision oncology | $836.9K / Pre-Seed / Feb 24, 2025 | ||
| The NADMED test was developed by one of the world's foremost experts on NAD metabolism in humans. NADMED's metabolite extraction system is the only method for measuring all four NADs and glutathione. | $3.9M / Series A / Aug 22, 2024 |
Co-Investors
Nordic Science Investments is a capital investment fund.
Nordic Science Investments Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alexandra Gylfe
Founding Partner
|
|||
Matti Hautsalo
Founding Partner
|
|||
Mart Maasik
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alexandra Gylfe invest in?
Alexandra Gylfe invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 5 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexandra Gylfe?
Public channels for Alexandra Gylfe include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexandra Gylfe last invest?
The most recent investment recorded for Alexandra Gylfe closed in Jun 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
